115 related articles for article (PubMed ID: 8013266)
1. Inhibition of Abelson oncogene function by erbstatin analogues.
Kawada M; Tawara J; Tsuji T; Honma Y; Hozumi M; Wang JY; Umezawa K
Drugs Exp Clin Res; 1993; 19(6):235-41. PubMed ID: 8013266
[TBL] [Abstract][Full Text] [Related]
2. Induction by some protein kinase inhibitors of differentiation of a mouse megakaryoblastic cell line established by coinfection with Abelson murine leukemia virus and recombinant SV40 retrovirus.
Honma Y; Okabe-Kado J; Kasukabe T; Hozumi M; Kajigaya S; Suda T; Miura Y
Cancer Res; 1991 Sep; 51(17):4649-55. PubMed ID: 1651810
[TBL] [Abstract][Full Text] [Related]
3. Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells.
Evans CA; Owen-Lynch PJ; Whetton AD; Dive C
Cancer Res; 1993 Apr; 53(8):1735-8. PubMed ID: 8467488
[TBL] [Abstract][Full Text] [Related]
4. A small molecule Abl kinase inhibitor induces differentiation of Abelson virus-transformed pre-B cell lines.
Muljo SA; Schlissel MS
Nat Immunol; 2003 Jan; 4(1):31-7. PubMed ID: 12469118
[TBL] [Abstract][Full Text] [Related]
5. Induction of morphological and enzymic differentiation in rat pheochromocytoma PC12h cells by stable erbstatin analogues.
Watanabe Y; Kakeya H; Ikoma E; Umezawa K
Drugs Exp Clin Res; 1993; 19(1):1-6. PubMed ID: 8223134
[TBL] [Abstract][Full Text] [Related]
6. Induction of morphological change by tyrosine kinase inhibitors in Rous sarcoma virus-transformed rat kidney cells.
Umezawa K; Tanaka K; Hori T; Abe S; Sekizawa R; Imoto M
FEBS Lett; 1991 Feb; 279(1):132-6. PubMed ID: 1704855
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
Jacquel A; Colosetti P; Grosso S; Belhacene N; Puissant A; Marchetti S; Breittmayer JP; Auberger P
Oncogene; 2007 Apr; 26(17):2445-58. PubMed ID: 17043649
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Druker BJ; Lydon NB
Cancer Res; 1996 Jan; 56(1):100-4. PubMed ID: 8548747
[TBL] [Abstract][Full Text] [Related]
10. c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
Huang HM; Liu JC
J Cell Physiol; 2009 Mar; 218(3):568-74. PubMed ID: 19006173
[TBL] [Abstract][Full Text] [Related]
11. A novel mutation within the kinase domain of v-abl gene responsible for temperature-sensitive colony-forming ability in soft agar.
Soma T; Tsukada S; Oka Y; Kishimoto T; Sugiyama H
Virology; 1993 Apr; 193(2):967-70. PubMed ID: 8460498
[TBL] [Abstract][Full Text] [Related]
12. Characterization of flat revertants isolated from cells transformed by Abelson murine leukemia virus (Ab-MuLV).
Oka T; Yutsudo M; Inoue H; Higuchi F; Hakura A
J Cell Physiol; 1990 Dec; 145(3):428-33. PubMed ID: 1703165
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of epidermal growth factor receptor functions by tyrosine kinase inhibitors in NIH3T3 cells.
Umezawa K; Sugata D; Yamashita K; Johtoh N; Shibuya M
FEBS Lett; 1992 Dec; 314(3):289-92. PubMed ID: 1468560
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of serum-induced M-phase progression by a tyrosine kinase inhibitor, erbstatin.
Sugata D; Yamashita K; Umezawa K
Biochem Biophys Res Commun; 1993 Jul; 194(1):239-45. PubMed ID: 8333839
[TBL] [Abstract][Full Text] [Related]
16. Effect of orthovanadate on commitment of avian myoblasts transformed with Rous sarcoma virus to myogenic differentiation.
Hase H; Isobe A; Kim J
Eur J Cell Biol; 1995 Nov; 68(3):313-22. PubMed ID: 8603684
[TBL] [Abstract][Full Text] [Related]
17. Effects of tyrosine kinase inhibitor on the motility and ATP concentrations of fowl spermatozoa.
Ashizawa K; Higashio M; Tsuzuki Y
Mol Reprod Dev; 1998 Feb; 49(2):196-202. PubMed ID: 9444662
[TBL] [Abstract][Full Text] [Related]
18. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia.
Kaur G; Gazit A; Levitzki A; Stowe E; Cooney DA; Sausville EA
Anticancer Drugs; 1994 Apr; 5(2):213-22. PubMed ID: 8049505
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of abl oncogene tyrosine kinase induces erythroid differentiation of human myelogenous leukemia K562 cells.
Honma Y; Okabe-Kado J; Kasukabe T; Hozumi M; Umezawa K
Jpn J Cancer Res; 1990 Nov; 81(11):1132-6. PubMed ID: 2125038
[TBL] [Abstract][Full Text] [Related]
20. Drosophila abelson interacting protein (dAbi) is a positive regulator of abelson tyrosine kinase activity.
Juang JL; Hoffmann FM
Oncogene; 1999 Sep; 18(37):5138-47. PubMed ID: 10498863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
